Campbell, Aideen M <br/><br/>
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.  [electronic resource] 

 -  BMJ open  12 2018 
 - e023115 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2044-6055 
<br/><br/><label>Standard No.: </label>10.1136/bmjopen-2018-023115  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anastrozole--therapeutic use<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemoprevention--methods<br/>Cross-Over Studies<br/>Disease-Free Survival<br/>Feasibility Studies<br/>Female<br/>Genetic Predisposition to Disease--epidemiology<br/>Goserelin--therapeutic use<br/>Heterozygote<br/>Humans<br/>Mutation<br/>Northern Ireland<br/>Patient Acceptance of Health Care--statistics & numerical data<br/>Patient Selection<br/>Premenopause--physiology<br/>Prognosis<br/>Risk Assessment<br/>Survival Rate<br/>Tamoxifen--therapeutic use<br/>Treatment Outcome<br/>Ubiquitin-Protein Ligases--genetics